Myeloid has dosed its first patient in the IMAGINE study, which is a Phase 1/2, multicenter, open-label, dose-escalation and dose cohort expansion clinical trial evaluating MT-101 in patients with refractory or relapsed PTCL. The dose-escalation portion of this Phase 1 study, with and without conditioning therapy, is open and enrolling patients.  Once Myeloid establishes the recommended Phase 2 dose, a Phase 2 trial will be initiated to support registration in this patient population.

MT-101 is being developed for the treatment of relapsed and refractory CD5-expressing T cell lymphomas. Refractory PTCL is a lethal disease with limited treatment options, that until now has not benefited from innovations in cell therapy. In vitro and in vivo studies show MT-101 demonstrated meaningful anti-tumor activity. Treatment in these models has been associated with potent phagocytosis responses, the production of inflammatory mediators and delays in tumor progression.  

Learn about Expanded Access

Patients

 We are actively recruiting patients to participate in clinical trials.  If you or your loved one has Peripheral T cell Lymphoma please see more information about the study below:

MT-101 IMAGINE Phase 1/2 Study